The Role of High-Density Lipoprotein in COVID-19

The Role of High-Density Lipoprotein in COVID-19

The current Coronavirus disease 2019 (COVID-19) pandemic has become a global challenge. Managing a large number of acutely ill patients in a short time, whilst reducing the fatality rate and dealing with complications, brings unique difficulties. The most striking pathophysiological features of pati...

Full description

Bibliographic Details
Main Authors:	Guyi Wang, Jiayi Deng, Jinxiu Li, Chenfang Wu, Haiyun Dong, Shangjie Wu, Yanjun Zhong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Pharmacology
Subjects:	COVID-19 SARS-CoV-2 lipoproteins HDL angiotensin-converting enzyme 2
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.720283/full

Similar Items

Evaluation of the Association between Multilobar Involvement and ACE Inhibitor Use in SARS-CoV-2 Patients
by: Dilay Satilmis, et al.
Published: (2023-01-01)

Dysregulation of the Renin-Angiotensin-Aldosterone System (RAA) in Patients Infected with SARS-CoV-2-Possible Clinical Consequences
by: Agnieszka Dettlaff-Pokora, et al.
Published: (2021-04-01)

Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection
by: Sarah Alabsi, et al.
Published: (2023-02-01)

The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19
by: Francesca Silvagno, et al.
Published: (2020-07-01)

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
by: Tümay Capraz, et al.
Published: (2021-12-01)

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study
by: Guyi Wang, et al.
Published: (2020-09-01)

Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity
by: Kyung-Hyun Cho, et al.
Published: (2021-02-01)

Pathophysiological Association of Endothelial Dysfunction with Fatal Outcome in COVID-19
by: Tatsuya Maruhashi, et al.
Published: (2021-05-01)

Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?
by: Seyed-Mohammad Ghahestani, et al.
Published: (2020-05-01)

SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis
by: Jincheng Xu, et al.
Published: (2020-07-01)

Histamine Potentiates SARS-CoV-2 Spike Protein Entry Into Endothelial Cells
by: Somasundaram Raghavan, et al.
Published: (2022-04-01)

High-density lipoprotein cholesterol: A marker of COVID-19 infection severity?
by: Aris P. Agouridis, et al.
Published: (2021-10-01)

Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant
by: Cosimo Cianfarini, et al.
Published: (2024-01-01)

Cognitive impact of COVID-19: looking beyond the short term
by: Scott Miners, et al.
Published: (2020-12-01)

Exploration of multifaceted molecular mechanism of angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various diseases
by: Aditi D. Kunvariya, et al.
Published: (2023-05-01)

A novel corona virus 2019 (COVID-19) outbreak: review article
by: Fateme Saljoughi, et al.
Published: (2021-02-01)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
by: Jing Ma, et al.
Published: (2021-05-01)

The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection
by: Jessica Maiuolo, et al.
Published: (2020-12-01)

In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2
by: Yamil Liscano, et al.
Published: (2020-11-01)

ACE2 Expression in the Cat and the Tiger Gastrointestinal Tracts
by: Roberto Chiocchetti, et al.
Published: (2020-08-01)

Lower Gene Expression of Angiotensin Converting Enzyme 2 Receptor in Lung Tissues of Smokers with COVID-19 Pneumonia
by: Francesca Lunardi, et al.
Published: (2021-05-01)

Neuropsychiatric Disorders and COVID-19: What We Know So Far
by: Fernanda Majolo, et al.
Published: (2021-09-01)

Characterization of ACE2 naturally occurring missense variants: impact on subcellular localization and trafficking
by: Sally Badawi, et al.
Published: (2022-09-01)

Dimethoxycurcumin Acidifies Endolysosomes and Inhibits SARS-CoV-2 Entry
by: Nabab Khan, et al.
Published: (2022-06-01)

Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
by: Yue Hu, et al.
Published: (2021-10-01)

Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator
by: Jingwei Bian, et al.
Published: (2021-01-01)

The pH Effects on SARS-CoV and SARS-CoV-2 Spike Proteins in the Process of Binding to hACE2
by: Yixin Xie, et al.
Published: (2022-02-01)

Smoking and SARS-CoV-2 Disease (COVID-19): Dangerous Liaisons or Confusing Relationships?
by: Giovanni Li Volti, et al.
Published: (2020-05-01)

Potential Impact of Diabetes and Obesity on Alveolar Type 2 (AT2)-Lipofibroblast (LIF) Interactions After COVID-19 Infection
by: Marjan Nouri-Keshtkar, et al.
Published: (2021-07-01)

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
by: Lianghui Zhang, et al.
Published: (2022-11-01)

Endothelial Dysfunction in SARS-CoV-2 Infection
by: Francesco Nappi, et al.
Published: (2022-03-01)

Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors
by: Ling Ma, et al.
Published: (2023-02-01)

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
by: Wentao Ni, et al.
Published: (2020-07-01)

The Looming Effects of Estrogen in Covid-19: A Rocky Rollout
by: Hayder M. Al-kuraishy, et al.
Published: (2021-03-01)

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?
by: Christian A. Devaux, et al.
Published: (2021-09-01)

The differences in virus shedding time between the Delta variant and original SARS-CoV-2 infected patients
by: Fanglin Li, et al.
Published: (2023-07-01)

Does Angiotensin II Peak in Response to SARS-CoV-2?
by: Léder Leal Xavier, et al.
Published: (2021-01-01)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
by: Ikram Omar Osman, et al.
Published: (2021-06-01)

ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues
by: Sally Badawi, et al.
Published: (2021-01-01)

High D-glucose levels induce ACE2 expression via GLUT1 in human airway epithelial cell line Calu-3
by: Yoshitaka Wakabayashi, et al.
Published: (2022-07-01)